|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 21.69 USD | -0.73% |
|
+6.06% | -17.43% |
| 07-30 | Fulgent Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026 | |
| 07-30 | Tranche Update on Fulgent Genetics, Inc.'s Equity Buyback Plan announced on March 8, 2022. | CI |
Company Valuation: Fulgent Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 3,001 | 900.1 | 856.7 | 564.9 | 812.1 | 596.5 | - | - |
| Change | - | -70% | -4.82% | -34.06% | 43.74% | -26.54% | - | - |
| Enterprise Value (EV) | 3,001 | 379.5 | 433.7 | 307.2 | 476.5 | 596.5 | 596.5 | 596.5 |
| Change | - | -87.35% | 14.29% | -29.16% | 55.08% | 25.2% | 0% | 0% |
| P/E | 6.14x | 6.43x | -5.13x | -13.1x | -13.3x | - | - | - |
| PBR | - | 0.69x | 0.76x | 0.53x | 0.73x | - | - | - |
| PEG | - | -0.1x | 0x | 0.2x | -0.3x | - | - | - |
| Capitalization / Revenue | 3.02x | 1.45x | 2.96x | 1.99x | 2.52x | 1.8x | 1.56x | 1.42x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.8x | 1.56x | 1.42x |
| EV / EBITDA | 0x | 0x | 0x | -0x | -0x | -7.95x | -14.5x | -20.6x |
| EV / EBIT | 0x | 0x | -0x | -0x | -0x | -4.03x | -4.89x | -5.01x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 16.38 | 4.63 | -5.63 | -1.41 | -1.97 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 992.6 | 619 | 289.2 | 283.5 | 322.7 | 331.7 | 382.7 | 420.2 |
| EBITDA 1 | 703.6 | 257.1 | 1.504 | -2.836 | -9.413 | -75 | -41 | -29 |
| EBIT 1 | 676 | 178.5 | -195.5 | -73.92 | -91.1 | -148 | -122 | -119 |
| Net income 1 | 507.4 | 143.4 | -167.8 | -42.71 | -60.51 | -112 | -79 | -73 |
| Net Debt | - | -520.6 | -423 | -257.7 | -335.6 | - | - | - |
| Reference price 2 | 100.59 | 29.78 | 28.91 | 18.47 | 26.27 | 21.69 | 21.69 | 21.69 |
| Nbr of stocks (in thousands) | 29,831 | 30,225 | 29,633 | 30,587 | 30,912 | 27,515 | - | - |
| Announcement Date | 2/23/22 | 2/28/23 | 2/28/24 | 2/28/25 | 2/27/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 601M | |
| -268.9x | 17.78x | -319.3x | -.--% | 52.8B | |
| 23.16x | 2.12x | 12.01x | 0.9% | 26.17B | |
| 16x | 1.26x | 7.18x | 5.47% | 6.89B | |
| 1111.14x | - | - | - | 6.12B | |
| 52.01x | 9.6x | 33.04x | 0.96% | 3.36B | |
| -31.28x | - | - | - | 3.13B | |
| -67.14x | - | - | -.--% | 2.56B | |
| 15.63x | 1.63x | 6.36x | 5.09% | 2.26B | |
| 30.7x | 1.59x | 11.9x | 1.47% | 1.85B | |
| Average | 97.92x | 5.66x | -41.47x | 1.99% | 10.57B | |
| Weighted average by Cap. | -63.56x | 11.16x | -175.16x | 0.82% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FLGT Stock
- Valuation Fulgent Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
